Clinical trial NCT02260609: GrafixCORE®: Open-Label Study to Evaluate the Safety and Efficacy of GrafixCORE® for Complex Diabetic Foot Wounds
Official title: A Multicenter, Open-label, Single-Arm Study to Evaluate the Safety and Efficacy of GrafixCORE® for the Treatment of Complex Diabetic Foot Wounds With Exposed Tendon and/or Bone
Study type: INTERVENTIONAL
Overall status: COMPLETED
Phase: PHASE4
Conditions: Complex Diabetic Foot Wounds
Keywords: Complex Wound
Diabetic Foot Ulcer
DFU
GrafixCORE
Exposed tendon
Exposed bone
Allograft tissue
Lead sponsor: Osiris Therapeutics
Sponsor class: INDUSTRY
First posted: 2014-10-09
Enrollment: 31
Sex: ALL
Minimum age (years): 18
Maximum age (years): 85
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Allocation: NA
Intervention model: SINGLE_GROUP
Primary purpose: TREATMENT

Brief summary: A multicenter, open-label, single-arm study to evaluate the safety and efficacy of GrafixCORE® for the treatment of complex diabetic foot wounds with exposed tendon and/or bone.


Eligibility criteria: Inclusion Criteria:

1. Between 18 years and 85 years of age inclusive, as of the date of screening
2. Confirmed diagnosis of Type I or Type II Diabetes
3. Index wound graded in the Texas Classification System as Grade II-III, Stage A or C (without active infection)
4. Wound is located on the foot below the malleoli
5. Wound accommodates up to three (3) 5 cm x 5 cm pieces of GrafixCORE® that completely cover the wound
6. Patient's wound extends through the dermis and into subcutaneous tissue with evidence of exposed muscle, tendon, bone, and/or joint capsule
7. Patient has adequate circulation to the foot as documented by either:

   * Ankle Brachial Index (ABI) ≥ 0.5 and ≤ 1.2, or
   * In patients with non-compressible ankle vessels, a Toe BP ≥ 40 mmHg or TcPO2 \> 30 mmHg, or
   * Skin perfusion pressure \> 30 mmHg

Exclusion Criteria:

1. Index Wound is of non-diabetic pathophysiology
2. Gangrene is present on any part of the affected foot
3. Index Wound is over a Charcot deformity
4. The longest dimension of the Index Wound exceeds 15 cm at the Baseline Visit
5. Patient has a glycated hemoglobin A1 (HbA1c) level of \>14%
6. Requiring intravenous (IV) antibiotics to treat the index wound infection at enrollment
7. Patient has a wound within 15cm of the Index Ulcer identified for study consideration
8. Patient is receiving oral or parenteral corticosteroids, immunosuppressive or cytotoxic agents
9. Patient is Human Immunodeficiency Virus (HIV) positive or has Acquired Immune Deficiency Syndrome (AIDS)
10. Current evidence of osteomyelitis, cellulitis, or other evidence of infection including fever or pus drainage from the wound site
11. Patient has active malignancy other than non-melanoma skin cancer
12. Patient's random blood sugar is \>450 mg/dl at screening
13. Patient has untreated alcohol or substance abuse at the time of screening, or is deemed to be non-adherent to the protocol by the Investigator
14. Pregnant women
15. Patient is currently enrolled or participated in another investigational device, drug, or biological trial within 30 days of screening
16. Patient has allergy to primary or secondary dressing materials used in this trial
17. Patient has had within the last 14 days, or is currently undergoing, or is planning for wound treatments with enzymes, growth factors, living skin, dermal substitutes or other advanced biological therapies
18. In the opinion of the Investigator, the patient is unsuitable for participation in the study

Primary outcomes:
measure: 100% granulation of wound as determined by the investigator
timeFrame: Up to 16 weeks after the Initial Treatment Visit
Secondary outcomes:
measure: Time to 100% granulation
timeFrame: Up to 16 weeks after the Initial Treatment Visit
measure: Number of applications of Grafix®
timeFrame: Up to 16 weeks after the Initial Treatment Visit
measure: Measurement of percent wound area reduction as determined by the investigator
timeFrame: Up to 16 weeks after the Initial Treatment Visit
measure: Closure of wound defined by 100% re-epithelialization
timeFrame: Up to 16 weeks after the Initial Treatment Visit
Other outcomes:
Locations:
city: Phoenix
country: United States
facility: Carl T. Hayden Medical Research Foundation
state: Arizona
city: Tucson
country: United States
facility: Southern Arizona VA Health Care System
state: Arizona
city: Miami
country: United States
facility: Miami VA
state: Florida
city: Weymouth
country: United States
facility: South Shore Hospital
state: Massachusetts
Study officials:
References: